The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.
Kyoto University investigator has been fired for research misconduct, while Nobel Laureate Shinya Yamanaka has been penalized for lack of oversight, Retraction Watch reports.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
